Skip to search formSkip to main contentSkip to account menu

Dipeptidyl-Peptidase IV Inhibitors

Known as: Dipeptidyl-Peptidase 4 Inhibitors, Inhibitors, Dipeptidyl-Peptidase IV, Dipeptidyl Peptidase 4 Inhibitors 
Compounds that suppress the degradation of INCRETINS by blocking the action of DIPEPTIDYL-PEPTIDASE IV. This helps to correct the defective INSULIN… 
National Institutes of Health

Related topics

Related topics

16 relations

Narrower (9)

ABT 341LinagliptinNN 7201alogliptin
Dipeptidyl Peptidase 4 Inhibitor [EPC]Dipeptidyl Peptidase 4 Inhibitors [MoA]Dipeptidyl Peptidase-4 InhibitorIn Blood

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
Toward Defining the Threshold Between Low and High Glucose Variability in Diabetes
OBJECTIVE To define the threshold for excess glucose variability (GV), one of the main features of dysglycemia in diabetes… 
Highly Cited
2016
Highly Cited
2016
Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006–2013
OBJECTIVE To examine temporal trends in utilization of glucose-lowering medications, glycemic control, and rate of severe… 
Review
2014
Review
2014
Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?
The proline-specific dipeptidyl aminopeptidase IV (DPP IV, DPP-4, CD26), widely expressed in mammalians, releases X-Pro/Ala… 
Review
2013
Review
2013
Adipo-Myokines: Two Sides of the Same Coin—Mediators of Inflammation and Mediators of Exercise
This review summarizes the current literature regarding the most discussed contraction-regulated moykines like IL-6, IL-15… 
Highly Cited
2012
Highly Cited
2012
Drug‐induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase‐IV inhibitors plus metformin
Background  Preclinical data and reports of adverse skin reactions in patients treated with dipeptidyl peptidase‐IV inhibitors… 
Review
2006
Review
2006
Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes
Inhibitors of the enzyme dipeptidyl peptidase IV (DPP IV) provide a strategy for the treatment of type 2 diabetes. DPP IV rapidly… 
Highly Cited
2006
Highly Cited
2006
Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form.
BACKGROUND Analysis of plasma B-type natriuretic peptide (BNP) has suggested the in vivo formation of a truncated form, BNP (3-32… 
Review
2003
Review
2003
Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IV
Dipeptidyl-peptidase IV/CD26 (DPP IV) is a cell-surface protease belonging to the prolyloligopeptidase family. It selectively… 
Review
2003
Review
2003
Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes
Incretins are peptide hormones, exemplified by glucose-dependent insulinotropic peptide and glucagon-like peptide 1 that are… 
Review
1998
Review
1998
Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
The insulinotropic hormone, glucagon-like peptide 1 (GLP-1), which has been proposed as a new treatment for type 2 diabetes, is… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)